Pharmaceuticals for the diagnosis and treatment of Alzheimer's disease

CN119685467BActive Publication Date: 2026-05-26SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
View PDF 1 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Filing Date
2024-11-26
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Current technologies struggle to diagnose and effectively treat Alzheimer's disease in its early stages, particularly regarding synaptic loss and calcium homeostasis imbalance at the pathological and neuronal functional levels, and lack effective biomarkers and therapeutic targets.

Method used

By identifying the high expression of the Maf1 gene or protein in neuronal cells as a diagnostic marker, and by regulating the binding of Maf1 to the promoter region of Grin1 to regulate the expression of NMDAR1, thereby affecting calcium homeostasis and synaptic function, a new diagnostic and therapeutic approach is provided, using small molecule compounds to intervene in the Maf1-NMDAR1 pathway.

Benefits of technology

It enables the possibility of early diagnosis of Alzheimer's disease and improves neuronal synaptic function, learning and memory abilities, and reduces pathological symptoms by regulating Maf1 expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention belongs to the field of biomedicine and relates to a biomarker for the early diagnosis of Alzheimer's disease and its application. Specifically, it discloses a biomarker for the early diagnosis of Alzheimer's disease, namely the Maf1 gene or its protein. High expression of the Maf1 gene or its protein in neuronal cells indicates that the test subject is in a high-risk group for Alzheimer's disease. This invention provides a new diagnostic and therapeutic target for AD.
Need to check novelty before this filing date? Find Prior Art